An orally available tubulin inhibitor, VERU-111, suppresses triple-negative breast cancer tumor growth and metastasis and bypasses taxane resistance

Triple-negative breast cancer (TNBC) accounts for ~15% of breast cancer cases in the United States. TNBC has poorer overall prognosis relative to other molecular subtypes due to rapid onset of drug resistance to conventional chemotherapies and increased risk of visceral metastases. Taxanes like pacl...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Cancer Ther
Egile Nagusiak: Deng, Shanshan, Krutilina, Raisa I, Wang, Qinghui, Lin, Zongtao, Parke, Deanna N., Playa, Hilaire C., Chen, Hao, Miller, Duane D., Seagroves, Tiffany N., Li, Wei
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7007836/
https://ncbi.nlm.nih.gov/pubmed/31645441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-0536
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak